Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: GTBL’s MicroBiopharm acquisition is a strategic move to become a more integrated, higher-value pharma services and ingredients player. The mai...
